Ginkgo Bioworks

DNANYSE United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$495.220 M

$7.97 -6.24%

Close of 7 Aug 2026

Revenue

$170.2M

#2355 by revenue

Earnings

-$313.0K

Loss-making

Shares outstanding

63,711,102

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#68Valneva SEVALN$502.9M
#69ProkidneyPROK$495.4M
#70Ginkgo BioworksDNA$495.2M
#71Kyverna TherapeuticsKYTX$483.9M
#72Cabaletta BioCABA$454.9M

Where these numbers come from

Share counts and financials for Ginkgo Bioworks are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.